WO2009137103A3 - Anti-cancer/anti-viral compounds and methods of use - Google Patents

Anti-cancer/anti-viral compounds and methods of use Download PDF

Info

Publication number
WO2009137103A3
WO2009137103A3 PCT/US2009/002883 US2009002883W WO2009137103A3 WO 2009137103 A3 WO2009137103 A3 WO 2009137103A3 US 2009002883 W US2009002883 W US 2009002883W WO 2009137103 A3 WO2009137103 A3 WO 2009137103A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
anti
methods
cancer
use
viral compounds
Prior art date
Application number
PCT/US2009/002883
Other languages
French (fr)
Other versions
WO2009137103A2 (en )
Inventor
Donald D. Ourth
Original Assignee
Ourth Donald D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Abstract

The invention provides compounds, compositions and methods for inhibiting, preventing and/or treating cancer and/or viral, helminthic, fungal, microbial, bacterial and/or protozoan infection, and/or insecticidal activity.
PCT/US2009/002883 2008-05-09 2009-05-08 Anti-cancer/anti-viral compounds and methods of use WO2009137103A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11847008 true 2008-05-09 2008-05-09
US12/118,470 2008-05-09

Publications (2)

Publication Number Publication Date
WO2009137103A2 true WO2009137103A2 (en) 2009-11-12
WO2009137103A3 true true WO2009137103A3 (en) 2010-01-07

Family

ID=41265234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/002883 WO2009137103A3 (en) 2008-05-09 2009-05-08 Anti-cancer/anti-viral compounds and methods of use

Country Status (1)

Country Link
WO (1) WO2009137103A3 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066783A (en) * 1986-05-20 1991-11-19 Cohen Eric A Antiviral peptides and means for treating herpes infections
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US6475985B1 (en) * 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US6734203B2 (en) * 2000-02-15 2004-05-11 Akira Matsuhisa Fused imidazolium derivatives
US20070072808A1 (en) * 2003-06-19 2007-03-29 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
US7320890B2 (en) * 2001-07-03 2008-01-22 University Of Utah Research Foundation Soluble steroidal peptides for nucleic acid delivery
US20080070966A1 (en) * 2006-06-14 2008-03-20 Elder Stewart T Anti-microbial compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066783A (en) * 1986-05-20 1991-11-19 Cohen Eric A Antiviral peptides and means for treating herpes infections
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US6475985B1 (en) * 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US6734203B2 (en) * 2000-02-15 2004-05-11 Akira Matsuhisa Fused imidazolium derivatives
US7320890B2 (en) * 2001-07-03 2008-01-22 University Of Utah Research Foundation Soluble steroidal peptides for nucleic acid delivery
US20070072808A1 (en) * 2003-06-19 2007-03-29 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
US20080070966A1 (en) * 2006-06-14 2008-03-20 Elder Stewart T Anti-microbial compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OURTH.: "Antiviral activity against human immunodeficiency virus-1 in vitro by myristoylated- peptide from Heliothis virescens.", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 320, no. 1, 16 July 2004 (2004-07-16), pages 190 - 196 *

Also Published As

Publication number Publication date Type
WO2009137103A2 (en) 2009-11-12 application

Similar Documents

Publication Publication Date Title
WO2011005341A3 (en) Compositions and methods related to protein a (spa) variants
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2009089494A3 (en) Pharmaceutical compositions
WO2007089903A3 (en) Cationic steroid microbial compositions for treating or preventing influenza infections
WO2008079460A3 (en) Tyrosine kinase inhibitors for prevention or treatment of infection
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2007011962A3 (en) Treatment of cancer
WO2008094545A3 (en) Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
WO2012083048A3 (en) Anti-viral compounds
WO2012083061A3 (en) Anti-viral compounds
WO2007079173A3 (en) Novel 2-heteroaryloxy-phenol derivatives as antibacterial agents
WO2007121125A3 (en) Hcv inhibitors
WO2008060795A3 (en) Antimicrobial articles and method of manufacture
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2007071455B1 (en) Sulfoximine-substituted pyrimidines , their preparation and use as drugs
WO2008121508A3 (en) Implantable medical devices fabricated from block copolymers
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2007027894A3 (en) Antisense compounds having enhanced anti-microrna activity
WO2009064767A3 (en) Bactericidal nanofibers, and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09743090

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09743090

Country of ref document: EP

Kind code of ref document: A2